1. Executive Session 6:00 - 6:30
   - Discussion on Medicaid OBRA’90/Supplemental Rebates and Agreements
     (as provided by 33 VSA § 1998(f)(2))

2. Introductions and Approval of DUR Board Minutes 6:30 - 6:35
   (Public Comment Prior to Board Action)

3. DVHA Pharmacy Administration Updates 6:35 - 6:45
   - Updates

4. Medical Director Update 6:45 - 6:50
   - Clinical Programs Update
   - Prescriber Comments

5. Follow-up Items from Previous Meetings 6:50 - 7:00
   - Atypical Antipsychotics – Pediatric Use

6. RetroDUR/DUR 7:00 – 7:00
   - None

7. Clinical Update: Drug Reviews 7:00 – 7:15
   (Public comment prior to Board action)
   **Abbreviated New Drug Reviews**
   - Edarbyclor® (azilsartan and chlorthalidone) Oral Tablet
   - Oxecta® (oxycodone)

   **Full New Drug Reviews**
   - Picato® (ingenol mebutate) Topical Gel

8. Therapeutic Drug Classes – Periodic Review 7:15 – 8:10
   (Public comment prior to Board action)
   **Class review documents available on DVHA web site 9/11/2012 @ 12 Noon**
   - Anti-hyperkinesis and Anti-Narcolepsy: ADHD
   - Anticonvulsants-Benzodiazepines
   - Incretin Mimetics (includes new drug review of Bydureon®)
   - Intranasal Corticosteroids
   - Ophthalmic Prostaglandin Analogues
9. New Managed Therapeutic Drug Classes 8:10 – 8:10
   (Public comment prior to Board action)
   - None

10. Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products 8:10 – 8:20
    (Public comment prior to Board action)
    - Scabicides and Pediculicides
    - Synagis® (palivizumab) 2012 Red Book Guideline Update

11. General Announcements 8:20– 8:30
    Selected FDA Safety Alerts
    - Ampyra® (dalfampridine): Drug Safety Communication - Seizure Risk for Multiple Sclerosis Patients
    - Codeine Use in Certain Children After Tonsillectomy and/or Adenoidectomy: Drug Safety Communication - Risk of Rare, But Life-Threatening Adverse Events or Death
    - Revatio® (sildenafil): Drug Safety Communication - Recommendation Against Use in Children

12. Adjourn 8:30